In early trading on the 21st, Alteogen is plunging more than 6%. Expectations had been high that a large-scale technology transfer deal mentioned at the JP Morgan Healthcare Conference would reach the trillion-won range, but it is seen as profit-taking driven by disappointment after the actual deal size disclosed the previous day turned out to be in the hundreds of billions of won.
As of 9:20 a.m. that day, on the KOSDAQ market, Alteogen is trading at 451,000 won, down 30,000 won (6.24%) from the previous trading day. Alteogen shares had surged more than 10% recently following remarks made at the JP Morgan Healthcare Conference (JPMHC).
Jeon Tae-young, president of Alteogen, said at JPMHC 2026 held in San Francisco on Jan. 15 local time, "We plan to announce a technology transfer for ALT-B4 as early as next week," adding, "It is expected to be similar in size to the previous transfer." The market expected, considering past technology transfer cases, that the deal size would reach the trillions of won.
However, the previous day Alteogen announced that it had signed a deal worth a total of 410 billion won with Tesaro, a U.S. GSK subsidiary, including 29.5 billion won in upfront payment and 390.5 billion won in milestones. As a result, it is seen that disappointment-driven selling is emerging and the share price is showing weakness.